Clinical N stage > 0, positive pre-therapy LN biopsy, ER positivity, PR positivity, Ki67 proliferative index < 50%, and patients with HR + /HER2 tumors predicted higher risk of residual lymph node disease. This evidence concerns the gene MKI67 and lymph node disorder.